Kitov
  • Home
  • About
    • Overview
    • Management
    • Board of Directors
  • Pipeline
    • Overview
    • Consensi™
    • NT-219
  • News
  • Investors
    • Welcome
    • Events
    • SEC Filings
    • Corporate Governance
    • Stock Information
    • Press Releases
    • Investor Alerts
    • Company Presentations
  • Contact Us
  • Home
  • About
    • Overview
    • Management
    • Board of Directors
  • Pipeline
    • Overview
    • Consensi™
    • NT-219
  • News
  • Investors
    • Welcome
    • Events
    • SEC Filings
    • Corporate Governance
    • Stock Information
    • Press Releases
    • Investor Alerts
    • Company Presentations
  • Contact Us
Kitov
  • Home
  • About
    • Overview
    • Management
    • Board of Directors
  • Pipeline
    • Overview
    • Consensi™
    • NT-219
  • News
  • Investors
    • Welcome
    • Events
    • SEC Filings
    • Corporate Governance
    • Stock Information
    • Press Releases
    • Investor Alerts
    • Company Presentations
  • Contact Us
  • Home
  • About
    • Overview
    • Management
    • Board of Directors
  • Pipeline
    • Overview
    • Consensi™
    • NT-219
  • News
  • Investors
    • Welcome
    • Events
    • SEC Filings
    • Corporate Governance
    • Stock Information
    • Press Releases
    • Investor Alerts
    • Company Presentations
  • Contact Us
About
Overview

Kitov Pharmaceuticals is an innovative biopharmaceutical drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov’s veteran team of healthcare professionals maintains a proven track record in streamlined end-to-end drug development and approval.

 

Kitov’s flagship combination drug, Consensi™, aims to treat osteoarthritis pain and hypertension simultaneously. Consensi™ achieved the primary efficacy endpoint for its Phase III clinical trial, and Kitov submitted a New Drug Application (NDA) in July 2017. The U.S. Food & Drug Administration (FDA) filed the NDA in September 2017, thereby accepting it for a full review. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target date of May 31, 2018, to complete its review.

 

Kitov’s newest drug, NT-219, is developed by its majority-held subsidiary TyrNovo. NT-219 is a first-in-class small molecule that targets IRS1/2 and STAT – two signal proteins that are part of an anti-cancer drug resistance mechanism. In various preclinical models where NT-219 was administered in combination with various oncology therapies, outstanding efficacy in preventing acquired resistance and reversing tumor resistance was demonstrated.

 

By lowering development risk and cost through fast-track regulatory approval of novel therapeutics, Kitov plans to deliver a rapid ROI and long-term potential to investors, while making a meaningful impact on people’s lives.

 

Founded in 2010, Kitov became a public company in 2013 when its shares were first traded on the Tel Aviv Stock Exchange (TASE). Kitov successfully issued an IPO on NASDAQ in November 2015. The company currently trades on both stock exchanges.

 

 

 

latest news

TyrNovo to Present at 2018 Annual Meeting of the American Association for Cancer Research

April 13, 2018

TyrNovo to Present at BIO-Europe Spring® 2018 Conference

March 8, 2018

Kitov Announces Consensi™ as Brand Name for KIT-302

December 14, 2017

Kitov Pharmaceuticals Announces Receipt of FDA's Favorable Response to NT219's pre-IND Meeting Package

November 1, 2017

Kitov Pharmaceuticals Announces Phase III/IV Clinical Trial for KIT-302 Successfully Meets Primary Endpoint, and also Demonstrates Drug Candidate Improves Renal Function

October 26, 2017
CONTACT US
CONTACT US
One Azrieli Center
Round Tower, Floor 19
132 Begin Road
Tel Aviv 670110 Israel

Tel. 972 3 9333121
Fax. 972 3 5097196
info@kitovpharma.com

© 2017 Kitov Pharmaceuticals Ltd. All rights reserved.
Scroll to top